Skip to content Skip to sidebar Skip to footer
Order Code

4709

Preferred Specimen

Collect 2 mL Serum using an SST tube. Allow it to clot in an upright position for at least 30 minutes, then centrifuge within 2 hours of collection. Refrigerate the specimen.

Container Type

Serum Separator Tube

Alternate Specimen Requirements

Acceptable alternatives include:

Collect 2 mL Serum in a plain red-top tube. Allow it to clot upright for at least 60 minutes, then centrifuge and transfer the serum into a plastic transport tube within 2 hours. Label the tube as Serum from Plain Red-Top Tube and Refrigerate.

Minimum Volume

  • 0.3 mL Serum

Transport Temperature

Refrigerated

Expected Turnaround Time

2 Days

Specimen Stability

  • Room Temperature: 24 hours
  • Refrigerated: 6 days
  • Frozen: 3 months

Methodology

Electrochemiluminescence Immunoassay (ECLIA)

Rejection Criteria

No more than one freeze/thaw cycle

Overview

Procalcitonin (PCT) is the precursor of the hormone calcitonin, which is normally produced by the thyroid C-cells and neuroendocrine cells of the lungs and intestines.
During systemic inflammation, especially bacterial infections, PCT production increases across various tissues and organs. Measuring these elevated levels helps identify bacterial infections and evaluate their severity.

In bacterial infections, PCT levels rise because bacterial endotoxins and cytokines block the conversion of PCT to calcitonin. In contrast, viral infections typically show low PCT levels, since cytokines like gamma interferon do not inhibit this conversion. Similarly, conditions such as gout, inflammatory bowel disease, arthritis, or the use of steroids and NSAIDs rarely cause a significant PCT increase (Gilbert, 2011).

PCT testing has been studied in two main patient groups — outpatients with respiratory tract infections and critically ill ICU patients (Hayashi, 2011). It also plays a role in reducing unnecessary antibiotic use for nonbacterial conditions and shortening treatment durations for bacterial infections.

Clinical Significance

  • Helps differentiate bacterial infections (requiring antibiotics) from viral or allergic causes.
  • Aids in the diagnosis of sepsis and infection severity assessment.
  • Monitors treatment response to antibiotics and guides therapy duration.
  • Supports antibiotic stewardship, minimizing overuse without affecting outcomes.
  • Assists in diagnosing pediatric pneumonia and renal involvement in pediatric urinary tract infections (UTIs).
Additional Information

In pediatric UTIs, PCT demonstrates higher sensitivity (90%) and specificity (88%) than C-reactive protein for identifying kidney involvement (Xu, 2014).
While calcitonin (CT) remains the main marker for medullary thyroid cancer (MTC), PCT testing offers advantages — studies show strong correlations between CT and PCT in MTC patients, suggesting PCT can serve as a complementary or alternative marker (Machens, 2014).

Interpretative Information

In healthy individuals, PCT ≤0.1 ng/mL is normal. Levels may become detectable within 2–4 hours of systemic inflammation, peaking within 24 hours.
PCT remains elevated during ongoing infection and drops by about 50% daily once effective treatment begins (Schuetz, 2011).

Newborns may show naturally high PCT levels during the first 24–72 hours after birth. However, those with early sepsis have significantly higher PCT values compared to uninfected newborns (Chiesa, 1998).

Cutoff Points for Interpretation

Lower Respiratory Tract Infections (Adults) (Clayton, 2013):

  • < 0.10 ng/mL – Bacterial infection very unlikely
  • 0.10 – < 0.25 ng/mL – Bacterial infection unlikely
  • 0.25 – < 0.50 ng/mL – Bacterial infection possible
  • ≥ 0.50 ng/mL – Suggestive of bacterial infection

Systemic Bacterial Infection / Sepsis (Adults) (Clayton, 2013):

  • < 0.50 ng/mL – Systemic infection unlikely
  • 0.50 – < 2.0 ng/mL – Possible systemic infection
  • 2.0 – < 10.0 ng/mL – Likely systemic infection; high risk for progression
  • ≥ 10.0 ng/mL – Severe sepsis or septic shock likely

Noninfectious Causes of Elevated PCT

  • Major trauma, surgery, burns, multiorgan failure
  • Addisonian crisis, pancreatitis, cirrhosis (Child-Pugh C)
  • Myocardial infarction, cardiogenic or hemorrhagic shock
  • Heat stroke, peritoneal dialysis
  • Certain cancers: medullary thyroid carcinoma, small-cell lung carcinoma, bronchial carcinoid
  • Treatment with interleukins or TNF-α
  • Parasitic (Plasmodium falciparum) and fungal infections
  • Newborns during the first two days of life

Limitations

  • Should not replace clinical judgment or microbiologic studies.
  • Early infections (<6 hours) may show false-negative results; repeat testing in 6 hours is advised.
  • Fibrin or particulate matter may lead to false-low readings.
  • Localized or subacute infections (e.g., endocarditis) may yield low PCT.
  • Antibiotic pretreatment can reduce PCT levels.
  • Rare high-dose hook effect may cause false-low results.

References

Agency for Healthcare Research and Quality. Evidence-based practice center systematic review protocol project title: procalcitonin for diagnosis and management of sepsis. 2011. http://www.effectivehealthcare.ahrq.gov/.

Agarwal R, Schwartz DN. Procalcitonin to guide duration of antimicrobial therapy in intensive care units: a systematic review. Clin Infect Dis. 2011;53(4):379-387.21810753

Bouadma L, Luyt CE, Tubach F, et al,.Use of procalcitonin to reduce patients’ exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial,” Lancet. 2010;375(9713):463-47420097417

Brooks M. FDA expands use of procalcitonin test to help guide ABX use. Medscape website. http://www.medscape.com/. Published February 24, 2017. Accessed February 28, 2017.

Chiesa C, Panero A, Rossi N, et al. Reliability of procalcitonin concentrations for the diagnosis of sepsis in critically ill neonates. Clin Infect Dis. 1998;26(3):664-672.9524841

Christ-Crain M, Stolz D, Bingisser R, et al, “Procalcitonin Guidance of Antibiotic Therapy in Community-Acquired Pneumonia: A Randomized Trial,” Am J Respir Crit Care Med, 2006, 174(1):84-3.16603606

Clayton J. Procalcitonin (serum, plasma). The Association for Clinical Biochemistry and Laboratory Medicine. http://www.acb.org.uk/. Published 2013. Accessed February 24, 2015.

Demissei BG, Cleland JG2, O’Connor CM, et al. Procalcitonin-based indication of bacterial infection identifies high risk acute heart failure patients. Int J Cardiol. 2016;204:164-171.26666342

Ebell M, “Procalcitonin-Guided Treatment of Respiratory Tract Infections,” Am Fam Physician, 2008 78(6):756-7.18819243

Gilbert DN. “Procalcitonin as a Biomarker in Respiratory Tract Infection,” Clin Infect Dis, 2011, 52(S4):S346-50.21460294

Jin M, Khan AI, “Procalcitonin: Uses in the Clinical Laboratory for the Diagnosis of Sepsis,” Lab Med, 2010, 41(3):173-7.

Kopterides P, Tsangaris I, “Procalcitonin and Sepsis: Recent Data on Diagnostic Utility Prognostic Potential and Therapeutic Implications in Critically Ill Patients,” Minerva Anestesiol, 2012, 78(7):823-35.22561677

Leroy S, Fernandez-Lopez A, Nikfar R, e al. Association of procalcitonin with acute pyelonephritis and renal scars in pediatric UTI. Pediatrics. 2013;131(5):870-879.23629615

Machens A, Lorenz K, Dralle H. Utility of serum procalcitonin for screening and risk stratification of medullary thyroid cancer. J Clin Endocrinol Metab. 2014;99(8):2986-2994.24840813

Mayo Medical Laboratories. Procalcitonin, serum. Clinical and Interpretative 2015.

McGee KA, Baumann NA, “Procalcitonin, Clinical Utility in Diagnosing Sepsis,” Clinical Laboratory News, 2009, 35(7):10-13.

Meisner Michael, Procalcitonin (PCT): A New, Innovative Infection Parameter Biochemical and Clinical Aspects, Germany Fa. BRAHMS Diagnostica GMBH, 2000, 174.

Schuetz P, Albrich W, Mueller B, “Procalcitonin for Diagnosis of Infection and Guide to Antibiotic Decisions: Past, Present and Future,” BMC Med, 2011, 9:10721936959

Schuetz P, Chiappa V, Briel M, et al “Procalcitonin Algorithms for Antibiotic Therapy Decisions: A Systematic Review of Randomized Controlled Trials and Recommendations for Clinical Algorithms,” Arch Intern Med, 2011, 171(15):1322-31.21824946

Schuetz P, Christ-Crain M, Thomann R, et al, “Effect of Procalcitonin-Based Guidelines vs Standard Guidelines on Antibiotic Use in Lower Respiratory Tract Infections: The ProHOSP Randomized Controlled Trial,” Jama, 2009, 302(10):1059-66.19738090

Simon L, Gauvin F, Amre DK, et al, “Serum Procalcitonin and C-Reactive Protein Levels as Markers of Bacterial Infection: A Systematic Review and Meta-Analysis,” Clin Infect Dis, 2004, 39(2):206-17.15307030

Simon P, Milbrandt EB, Emlet LL. Procalcitonin-guided antibiotics in severe sepsis. Crit Care. 2008;12(6):309.19090974

van Rossum AM, Wulkan RW, Oudesluys-Murphy AM. Procalcitonin as an early marker of infection in neonates and children. Lancet Infect Dis. 2004;4(10):620-630.15451490

Xu RY, Liu HW, Liu JL, Dong JH. Procalcitonin and C-reactive protein in urinary tract infection diagnosis. BMC Urol. 2014 May;14:4524886302

Diagnostic Role

PCT is among the earliest and most specific markers for bacterial infections, valuable for monitoring disease progression and treatment response.
While cultures remain the gold standard, results take 24–48 hours. PCT can yield results within hours, making it useful in emergency and ICU settings.

  • < 0.1 ng/mL strongly supports a nonbacterial cause.
  • > 2.0 ng/mL on ICU admission suggests high risk for severe sepsis.
  • A > 30% drop after 24 hours of antibiotics indicates treatment success.

PCT testing (e.g., Vidas Brahms PCT assay) has FDA approval for guiding antibiotic initiation or discontinuation in lower respiratory infections and sepsis (Brooks, 2017).
It should always be interpreted alongside clinical findings, as empiric antibiotics may still be necessary even with normal PCT levels in high-risk cases.

Test Setup Days

Monday through Friday AM shift

CPT

84145 LOINC:75241-0

Reference Range

<0.10 NG/ML

UNIT CODEUNIT CODE NAMEANALYTEGENDERAGEREFERENCE RANGEUNITS OF MEASURE
4709PROCALCITONINPROCALNOT SPECIFIEDALL<0.10NG/ML
4709PROCALCITONINPROCALMALEALL<0.10NG/ML
4709PROCALCITONINPROCALFEMALEALL<0.10NG/ML

Leave a comment

Receive News

Subscribe for the Updates!